|
|
Article: WEX Starts Phase III Trial of Tectin(TM) for Cancer Pain
- Article from:
- CCNMatthews Newswire
- Article date:
- April 8, 2008
CopyrightCopyright 2008 CCNMatthews Newswire. Provided by ProQuest LLC. (Hide copyright information)
|
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 8, 2008) - WEX
Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced
today the enrolment and dosing of the first patient in a Phase III
clinical trial of Tectin(TM), the Company's lead product candidate,
for cancer pain. This clinical trial (TEC-006) is a multicentre,
randomized, double-blind and placebo-controlled trial comparing the
efficacy and safety of Tectin(TM) to placebo in approximately 120
patients with moderate to severe inadequately controlled cancer-
related pain.
Trial Design
The objective of the TEC-006 trial is to evaluate the efficacy
and safety of Tectin(TM) vs. placebo in patients with inadequately
controlled ...